X0306 4 2019-04-08 0 0001397702 Silk Road Medical Inc SILK 0001772583 Norwest Venture Partners XIII, LP 525 UNIVERSITY AVENUE SUITE 800 PALO ALTO CA 94301 0 0 1 0 0001535261 Crowe Jeffrey 525 UNIVERSITY AVENUE SUITE 800 PALO ALTO CA 94301 0 0 1 0 0001726084 Kossow Jon Erik 525 UNIVERSITY AVENUE SUITE 800 PALO ALTO CA 94301 0 0 1 0 0001089744 HAQUE PROMOD 525 UNIVERSITY AVENUE SUITE 800 PALO ALTO CA 94301 0 0 1 0 Common Stock 2019-04-08 4 C 0 2458210 A 2458210 D Common Stock 2019-04-08 4 X 0 3764 8.27 A 2461974 D Series C Preferred Stock 2019-04-08 4 C 0 2458210 0.00 D Common Stock 2458210 0 D Warrant (Right to buy) 8.27 2019-04-08 4 X 0 3764 0.00 D 2024-12-21 Common Stock 3764 0 D The securities shown on Lines 1 and 2 of Table I and Lines 1 and 2 of Table II represent securities held of record by Norwest Venture Partners XIII, LP ("NVP XIII"). Genesis VC Partners XIII, LLC ("Genesis XIII") is the general partner of NVP XIII and may be deemed to have sole voting and dispositive power over the shares held by NVP XIII. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XIII, and Promod Haque, Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities and Haque, Crowe, and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. All of the shares subject to the warrant are fully exercisable as of the date hereof. /s/ Matthew De Dominicis, Chief Financial Officer 2019-04-10